The Growth Driver Johnson & Johnson Investors Need to Watch
The Growth Driver Johnson & Johnson Investors Need to Watch
Thanks to launches overseas, non-U.S. sales jumped 89% to $ 284 million, bringing global sales to $ 1.7 billion in 2013. Another success is anti-coagulant drug Xarelto. Xarelto is one of three recently launched competing treatments challenging warfarin's …
Read more on Motley Fool
Spectrum Pharmaceuticals, Inc. (SPPI) news: Analysis Of The Near-Term Value …
Marqibo is a new formulation of the anticancer drug vincristine for the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL). Marqibo received orphan status to treat Ph-ALL … Folotyn is used on refractory …
Read more on Seeking Alpha
More Drug Treatment News 2013 Information…